EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist

Eric Ernest Prommer

Journal of Opioid Management · 2025

DOI: 10.5055/jom.0958 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Opioid Management, 2025. Verfasst von Eric Ernest Prommer. Beteiligte Einrichtung: University of California Los Angeles. Hauptthemen laut MEDLINE: Analgesics, Opioid, Spiro Compounds, Acute Pain, Thiophenes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oliceridine is the first Food and Drug Administration-approved biased opioid agonist, approved in 2020 for managing moderate to severe acute pain in adults in controlled clinical settings. The advantages of the drug are its potency and decreased opioid-related adverse effects compared to morphine. The rationale for its potency, and especially the decreased adverse effects, is its purported preferential G protein signaling over β-arrestin recruitment, favoring less opioid-related adverse effects. Further research has led to questions as to the actual mechanism of action of the drug, leading to additional questions about whether it is a genuinely biased opioid agonist. This paper examines the mechanism of action, pharmacology, adverse effects, and clinical evidence accumulated to date regarding its effectiveness as a potent analgesic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidSpiro CompoundsAcute PainThiophenesReceptors, OpioidHumansUnited StatesUnited States Food and Drug AdministrationDrug ApprovalAnimals

Substanzen

Analgesics, Opioid((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineSpiro CompoundsThiophenesReceptors, Opioid

Autor:innen und Institutionen

  • University of California Los Angeles.

Zitieren

APA

Prommer, E. E. (2025). Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist. Journal of Opioid Management. https://doi.org/10.5055/jom.0958

Vancouver

Prommer EE. Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist. Journal of Opioid Management. 2025. doi:10.5055/jom.0958

BibTeX
@article{Prommer2025,
  author = {Prommer, Eric Ernest},
  title = {Oliceridine: Examining the clinical evidence, pharmacology, and contested mechanism of action of the first FDA-approved biased opioid agonist},
  journal = {Journal of Opioid Management},
  year = {2025},
  doi = {10.5055/jom.0958}
}
Kostenlos starten →